A case report: clinically benign anti-Csa

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

4
Reader(s)
4
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 6 , ISSUE 3 (September 1990) > List of articles

A case report: clinically benign anti-Csa

Thom Sererat / Jan Alexander / Jack Beatty

Citation Information : Immunohematology. Volume 6, Issue 3, Pages 71-72, DOI: https://doi.org/10.21307/immunohematology-2019-1044

License : (Transfer of Copyright)

Published Online: 20-December-2020

ARTICLE

ABSTRACT

Previous reports on the clinical significance of anti-Csa(Cost-Stirling) have presented conflicting data. We report our findings, over an 8-month period, of a patient whose serum contained anti-Csa and anti-Fya. Nineteen donor units of ABO and Rh-matched, Fya-negative red cells, which were crossmatch incompatible, were transfused with no clinical, serological, or biochemical evidence of a hemolytic transfusion reaction.

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share